Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus switch versus reduced calcineurin inhibitor immunosuppression for BK virus nephropathy after kidney transplantation
2008-005925-12Phase 4Terminated
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Dec 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus, cyclosporine and tacrolimus in BK polyomavirus associated nephropathy (BKPyVAN) (2 arms), sponsored by Medizinische Hochschule Hannover. Primary endpoint: Primary composite endpoint. Started Dec 2010; status: terminated.
02
Drugs
everolimuscyclosporinetacrolimus
03
Conditions
BK polyomavirus associated nephropathy (BKPyVAN)
Beyond the preview
Go deeper on 2008-005925-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005925-12.